Assesses the percentage of children and adolescents with ongoing antipsychotic medication use who had metabolic testing during the year.
Why It Matters
Antipsychotic prescribing for children and adolescents has increased rapidly in recent decades.1,2 These medications can elevate a child’s risk for developing serious metabolic health complications3,4 associated with poor cardiometabolic outcomes in adulthood.5 Given these risks and the potential lifelong consequences, metabolic monitoring (blood glucose and cholesterol testing) is an important component of ensuring appropriate management of children and adolescents on antipsychotic medications.
Metabolic Monitoring for Children and Adolescents on Antipsychotics
|Measure Year||Commercial HMO||Commercial PPO||Medicaid HMO|
This State of Healthcare Quality Report classifies health plans differently than NCQA’s Quality Compass. HMO corresponds to All LOBs (excluding PPO and EPO) within Quality Compass. PPO corresponds to PPO and EPO within Quality Compass.
Figures do not account for changes in the underlying measure that could break trending. Contact Information Products via my.ncqa.org for analysis that accounts for trend breaks.
- Patten, S.B., W. Waheed, L. Bresee. 2012. “A review of pharmacoepidemiologic studies of antipsychotic use in children and adolescents.” Canadian Journal of Psychiatry 57:717–21.
- Cooper, W.O., P.G. Arbogast, H. Ding, G.B. Hickson, D.C. Fuchs, and W.A. Ray. 2006. “Trends in prescribing of antipsychotic medications for US children.” Ambulatory Pediatrics 6(2):79–83.
- Correll, C. U., P. Manu, V. Olshanskiy, B. Napolitano, J.M. Kane, and A.K. Malhotra. 2009. “Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.” Journal of the American Medical Association
- Andrade, S.E., J.C. Lo, D. Roblin, et al. December 2011. “Antipsychotic medication use among children and risk of diabetes mellitus.” Pediatrics 128(6):1135–41.
- Srinivasan, S.R., L. Myers, G.S. Berenson. January 2002. “Predictability of childhood adiposity and insulin for developing insulin resistance syndrome (syndrome X) in young adulthood: the Bogalusa Heart Study.” Diabetes 51(1):204–9.